Paxman AB (publ) (PAX) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

And today we're hosting Paxman's Q2 presentation. And with me here I have Richard Paxman, CEO of Paxman. Welcome, Rich. Hi, good to see you. And the format is as usual. You take us through the quarter, Rich, and talk about recent developments and what you've seen and so on. And now we continue with the Q&A session. And I remind you all guys to ask questions in the chat. It is live and I will be on the lookout for your questions. So now it's over to you, Rich. Please. Fantastic. Thank you, Maria. And good morning, everyone. Hope you're as happy with our report as we are. As you've seen, group sales amounted to just over 105 million SECs. So we've hit that 100 mark for the first time in our history, which is fantastic. And that's a 40% growth. Abhimanyu Sharma, Chief Executive Officer, Abhimanyu Sharma Foundation I think the biggest highlight we've all seen in the report is our growth in insurance-based billing. And that has, and I'll say finally, because I think we've all been waiting on it, some momentum. And that's really about adoption of the insurance-based billing model and that drive in utilization, which we'll touch on shortly. So our U.S. revenues for Paxman and the group achieved 7.1 million SEC for the quarter. And then I think one of the most significant pieces of news this quarter relates to the revised approach for our neuropathy device. And we'll talk a little bit about that. But now going down the de novo route. which again timelines are frustrating but we've got a clear pathway and not too much delayed and so excited about the opportunity still So for the first time, we put in some new KPIs and hopefully you like some of these, really focusing on those US revenues and that sort of differentiation between the different models. Again, showing that really...